tiprankstipranks
Trending News
More News >
Orthocell Ltd (AU:OCC)
ASX:OCC
Australian Market
Advertisement

Orthocell Ltd (OCC) AI Stock Analysis

Compare
61 Followers

Top Page

AU:OCC

Orthocell Ltd

(Sydney:OCC)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
AU$1.00
▼(-12.28% Downside)
Orthocell Ltd's overall stock score is primarily influenced by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, and the valuation reflects ongoing losses with a negative P/E ratio. The absence of earnings call and corporate events data limits additional insights.

Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)

Orthocell Ltd Business Overview & Revenue Model

Company DescriptionOrthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
How the Company Makes MoneyOrthocell Ltd generates revenue through the sale and licensing of its proprietary regenerative medicine products and technologies. The company's key revenue streams include the commercial distribution of CelGro for use in various surgical procedures and the provision of its cell therapy solutions, Ortho-ATI and Ortho-ACI, to healthcare providers and institutions. Additionally, Orthocell may engage in strategic partnerships and collaborations with other companies and research organizations, potentially contributing to its earnings through licensing fees, milestone payments, and royalties. The company's revenue model is underpinned by its focus on expanding market adoption and obtaining regulatory approvals to broaden its product offerings and geographic reach.

Orthocell Ltd Financial Statement Overview

Summary
Orthocell Ltd is experiencing revenue growth, but profitability remains a significant challenge with negative margins and returns. The balance sheet is stable with low leverage, but cash flow issues persist, impacting the company's ability to generate positive cash flow from operations.
Income Statement
45
Neutral
Orthocell Ltd has shown a positive revenue growth rate of 19.57% in the latest year, indicating a growing top line. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has decreased slightly from the previous year, suggesting some pressure on cost management.
Balance Sheet
50
Neutral
The company maintains a low debt-to-equity ratio of 0.04, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, suggesting a strong capital structure, but the negative ROE highlights profitability challenges.
Cash Flow
40
Negative
Orthocell Ltd has improved its free cash flow growth rate by 12.12%, but the operating cash flow remains negative, indicating cash flow challenges. The free cash flow to net income ratio is above 1, suggesting that the company is generating cash flow relative to its net losses, but the overall cash flow position is weak.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.40M7.55M5.32M4.24M1.53M1.02M
Gross Profit3.58M4.80M3.69M3.06M832.52K299.88K
EBITDA-11.77M-13.43M-11.68M-9.93M-11.52M-11.67M
Net Income-8.57M-8.57M-7.18M-6.25M-9.11M-9.04M
Balance Sheet
Total Assets35.24M35.24M26.62M29.61M37.90M19.33M
Cash, Cash Equivalents and Short-Term Investments28.62M28.62M20.61M24.82M11.02M16.33M
Total Debt576.89K576.89K689.69K562.30K507.56K621.72K
Total Liabilities20.67M20.67M22.08M23.46M27.99M2.46M
Stockholders Equity14.57M14.57M4.53M6.15M9.90M16.87M
Cash Flow
Free Cash Flow-8.94M-9.04M-7.45M13.96M-6.80M-4.82M
Operating Cash Flow-8.68M-8.68M-6.51M14.59M-6.26M-4.63M
Investing Cash Flow-359.06K-359.06K-942.02K-631.56K-535.02K-188.52K
Financing Cash Flow17.05M17.05M3.24M-164.61K1.49M709.15K

Orthocell Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.14
Price Trends
50DMA
1.22
Negative
100DMA
1.24
Negative
200DMA
1.31
Negative
Market Momentum
MACD
-0.02
Negative
RSI
45.72
Neutral
STOCH
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.22, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OCC.

Orthocell Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
114.23M-4.380.00%0.00%0.66%
50
Neutral
366.97M-5.920.00%0.00%-19.21%
46
Neutral
306.09M-21.430.00%1271.12%36.87%
45
Neutral
AU$280.78M-89.70%42.05%-0.84%
40
Underperform
117.36M-5.730.00%-20.79%73.98%
40
Underperform
105.34M-12.940.00%700.00%26.88%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:OCC
Orthocell Ltd
1.14
0.69
153.33%
PBIGF
Paradigm Biopharmaceuticals
0.18
0.04
28.57%
PRRUF
Immutep Ltd
0.19
-0.04
-17.39%
AU:DXB
Dimerix Limited
0.51
0.13
34.21%
AU:RCE
Recce Pharmaceuticals Ltd.
0.40
-0.11
-21.57%
AU:ALA
Arovella Therapeutics Limited
0.09
-0.07
-43.75%

Orthocell Ltd Corporate Events

Orthocell Expands Remplir’s Use in Prostate Cancer Surgeries
Sep 16, 2025

Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Announces 2025 AGM and Director Nomination Deadline
Sep 10, 2025

Orthocell Limited has announced that its 2025 Annual General Meeting will be held on November 6, 2025, with the re-election of directors as a key agenda item. The closing date for director nominations is September 18, 2025. This announcement is part of Orthocell’s ongoing efforts to strengthen its governance structure as it continues to expand its market presence globally, particularly in the US with its regenerative medicine products.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell’s Remplir Study Shows 81% Success Rate, Boosting US and EU Expansion Plans
Sep 8, 2025

Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Expands Share Base with New Issuance
Sep 3, 2025

Orthocell Limited has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options, allowing these shares to be traded immediately. This move is part of the company’s compliance with the Corporations Act, potentially enhancing its market operations and providing liquidity for stakeholders.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Issues New Securities to Strengthen Market Position
Sep 3, 2025

Orthocell Ltd has announced the issuance of 1,500,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategic efforts to enhance its capital structure, potentially strengthening its market position and providing additional resources for its ongoing projects in regenerative medicine.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Appoints New Director, Strengthening Strategic Direction
Sep 1, 2025

Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options and 56,169 ordinary fully paid shares through McNulty Family Pty Ltd and his spouse, indicating a significant personal investment in the company. This appointment may enhance Orthocell’s strategic direction and strengthen its position in the regenerative medicine sector.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Issues Unquoted Options to Enhance Strategic Flexibility
Sep 1, 2025

Orthocell Ltd announced the issuance of 2,000,000 unquoted options, set to expire on August 31, 2028, with an exercise price of $1.53. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and offering strategic flexibility in its financial operations.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Appoints New Director, Enhancing Leadership
Sep 1, 2025

Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options through McNulty Family Pty Ltd, exercisable at $1.53 and expiring on August 31, 2028. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and stakeholder relations positively.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 18, 2025